Introduction
Allogeneic haemopoietic SCT (allo-HSCT) is a treatment modality that offers the greatest potential for cure for many haematological malignancies. However, relapse post-transplant is still a very significant obstacle to the prospect of long-term survival. Chemotherapy for treatment of relapse post-allo-HSCT is typically associated with a poor salvage rate and a high treatment-related mortality. Presence of donor chimerism allows for acceptance, and further proliferation of infused donor immune effector cells, including natural killer (NK) cells and T cells. Donor lymphocyte infusion (DLI) with T cells has become an established and commonly adopted modality in the management of relapse in such a setting, with the greatest efficacy observed in relapsed CML. 1, 2 Graft vs tumour effect augmented by donor T cells has also been demonstrated in low grade lymphoma, 3 CLL, 3 Hodgkin's disease (HD), 4 as well as multiple myeloma, 5, 6 and to a lesser extent in AML, myelodysplastic syndrome and ALL. 7 For NK cells, the rapidly accumulating knowledge over the past few years has facilitated clinical studies, exploiting the alloreactivity of donor NK cell infusion in the prevention and treatment of relapse in a non-transplant setting. 8, 9 Cytokine-induced killer (CIK) cells are polyclonal T cells that can be expanded from marrow or PBLs with potent non-MHC-restricted cytotoxicity against a variety of tumour target cells. Earlier work established the superiority of CIK cells over lymphokine-activated killer (LAK) cells in terms of expansion and cytotoxicity. 10, 11 Potent in vitro cytotoxicity against various chemo-resistant tumour cell lines, 12 lymphoma, 10, 11 and primary AML 13 and CML cells 14 had been reported. CIK cells 15, 16 and other ex vivo expanded polyclonal T cells 17 have been used as an activated form of DLI in the post-allo-HSCT setting. Feasibility and safety were shown, as well as efficacy in some cases. 15 One major concern is the possibility of more severe GVHD associated with the infusion of T cells activated in vitro. This seems not to be the case with the limited reports currently available. [15] [16] [17] On the other hand, whether activated donor T cells are superior to unmanipulated donor lymphocytes is an important question.
Activated donor T-cell therapy, which requires special facilities and expertise in its production, is an expensive cellular product as compared with un-manipulated DLI, and therefore its role has to be defined before adopting for routine use. There seems to be suggestion of such superiority in a few reported cases. 15 Here, we present our Phase I/II clinical study on the use of allogeneic CIK cells for patients who have failed conventional DLI to explore the efficacy of CIK cells in the presence of DLI failure and define the role of CIK cells in the management of relapse post-allo-HSCT.
Patients and methods

Inclusion and exclusion criteria
This clinical study included patients who had relapsed after an allogeneic transplant and (1) who had not responded to at least one dose of DLI given either alone or together with any form of chemotherapy chosen based on individual case basis, and (2) those who had no access to further donor lymphocytes for repeated doses of DLI, as in umbilical cord blood transplant (UCBT) or some cases of unrelated donor transplant, but still with donor chimerism. Patients must not have active uncontrolled acute GVHD or be on any immunosuppressants at the time of CIK infusion, but stable chronic GVHD was not excluded when a benefit of potential Graft vs tumour effect was deemed to outweigh the risk. Cytopenia and impaired renal or liver function were not exclusion criteria, as these are common problems in such patients. The study was approved by the Institutional Review Board and registered with Clinicaltrial.gov as a Phase I/II study (Protocol number NCT00460694). All patients gave informed consent and the study was carried out in accordance with the Helsinki Declaration.
Large scale CIK cell expansion
This was adapted from expansion in flasks to bags in a cell therapy facility with compliance to good manufacturing practice requirements. Donor cells may be (1) mobilized PBSCs from donors collected and frozen during the procedure of PBSC harvesting, or (2) cells harvested from the donor at steady state for the purpose of DLI, either fresh or frozen. In addition, in patients who had relapsed in whom further donor cells are not available as mentioned in (2) under inclusion criteria, leukapheresis to collect donor cells from patients was carried out for expansion into CIK cells.
Fresh cells underwent ficol hypaque (GE Healthcare, Uppsala, Sweden) centrifugation to isolate mononuclear cells, whereas frozen cells were thawed and washed. Cells were cultured in 10% defined FCS (Hyclone, Logan, UT, USA)/RPMI (Invitrogen, Carlsbad, CA, USA) in life-cell culture bags (Baxter, Deerfield, IL, USA) with IFN-g (Imukin, Boehringer Ingelheim, Wien, Austria) at 1000 IU/ mL added on day 1 (D1), IL-2 (Proleukin, Novartis, Basel, Switzerland) at 300 IU/mL and OKT3 (Orthoclone, Janssen-Cilag, Schaffhausen, Switzerland) at 50 ng/mL added on D2. Starting from D11, media was topped up every 3-4 days to keep cell concentration at 2 million cells/mL, and IL-2 added every 6-7 days. At about D28 þ /À 1 day, cells were harvested with an automated cell harvester, COBE 2991 (CaridianBCT Inc, Lakewood, CO, USA), and frozen in aliquots of 10-100 million CD3/kg for future use. Release criteria mandated a pre-freeze viability of more than 70%, satisfaction of negative culture for bacteria and fungus, and negative endotoxin and mycoplasma tests.
Laboratory assays
Cell-surface immunophenotype for CD3FITC(UCHT1), CD8FITC(B9.11) and CD127PE(R34.34) (Beckman Coulter, Marseille, Fance), CD56PE(B159), CD4PE(RPA-T4), PD-1PE(MIH4), CD25FITC(M-A251) (BD Bioscience, San Jose, CA, USA) and NKG2DPE(1D11) (eBiosceince, San Diego, CA, USA) by flow cytometry and cytotoxicity measured by chromium release assay (Perkin Elmer, Boston, MA, USA) were done as previously described. 13 Allogeneic AML blasts from an unrelated patient's sample frozen in multiple vials at diagnosis was used as the target.
Schedule of CIK cell infusion
Patients at relapse post-allo-HSCT were treated with various regimens of oral or i.v. chemotherapy, with DLI on the basis of individualized decisions made by the attending haematologist. CIK infusions were given at the nadir of lymphopenia at about 1-2 weeks after chemotherapy, if chemotherapy was given. Dose and schedule of CIK cells were guided by the following principles with flexibility for modification based on individual case consideration. The first dose of CIK cells for patients who have already received DLI without response will be double or triple the last DLI dose, expressed as CD3 þ cells/kg. Subsequent infusions were given at a minimum of 4-weekly intervals, with dose doubled or tripled depending on the availability of CIK cells if no response was observed, and remaining the same if there was response. In the presence of GVHD, infusion will be withheld until its resolution, and resumed at half or one-third of the previous dose. There was no limitation to the number of CIK infusions, which was allowed as long as cells were available and clinical benefit was deemed to outweigh potential risk. Patients were premedicated with i.v. diphenhydramine, p.o. celecoxib and p.o. paracetamol at 0.5-1 h before rapid infusion of CIK cells thawed at bedside.
Assessment of adverse reaction and efficacy
All patients had monitoring of vital signs for 3 h after infusion and were followed up closely as in standard clinical practice. Blood biochemistries and full blood counts were done weekly or at most fortnightly depending on clinical indication. Marrow studies and imaging were done when clinically indicated to assess response. Designation of response for the various diseases were based on defined published criteria. 18, 19 Efficacy of CIK therapy was inferred on the basis of a detailed analysis of the subsequent clinical course and classified according to the following arbitrarily set definitions: (1) Evidence suggestive of efficacy, defined by either durable or non-durable but demonstrable response attributable to CIK cell activity based on the nature of treatment and response; (2) Absence of efficacy, defined by persistence of measurable tumour load that did not improve after CIK infusion and (3) Unable to assess, where any clinical response whether durable or not, might be due to the effect of concomitant chemotherapy such that any remission could not be conclusively attributed to CIK cells activity.
Results
Feasibility of CIK cell expansion
A total of 24 patients, including 15 with a fully matched sibling donor, 8 with a HLA-A, B, C and DRB1 highresolution fully matched unrelated donor, and 1 with a single unit cord blood transplant satisfied the inclusion criteria for this study. A total of 34 CIK cell cultures were expanded for these 24 patients. One culture failed to expand into CIK cells without obvious reason on the first attempt but succeeded the second time. These 24 patients included 5 with no access to further donor cells who underwent leukapheresis and successfully expanded CIK cells from harvested allogeneic cells. This included one UCBT, three unrelated donor and one sibling transplant. Figure 1 shows a breakdown of these cases according to whether CIK cells were generated from donor or patients, by type of disease and the number of sessions of infusion for the 16 patients who eventually received CIK cell infusion.
The overall median CD3 þ T-cell expansion was 9.33 (1.3-38.97) fold and CD3 þ CD56 þ NK-like T-cell expansion was 27.77 (2.59-438.93) fold. Table 1 shows the comparison of the pre-and post-culture characteristics of the 23 cultures from 20 allogeneic donors and the 10 cultures from 5 patients (1 patient had CIK cultures from both his donor and himself on different occasions). It showed feasibility of generating CIK cells from leukapheresis products harvested from patients. Proportions of CD3 þ cells pre-culture were comparable between the two groups and showed a wide range of variation as expected.
Fold expansion of CD3
þ and CD3 þ CD56 þ subsets, as well as cytotoxicity against a common allogeneic AML blast target at the end of culture, was comparable between the two groups. The proportion of the CD3 þ CD56 þ subset was significantly higher in CIK cultures derived from patients than those derived from donors, which is consistent with our previous observation on autologous CIK cells derived from patients. 20 Supplementary File 1 shows the flourescein-activated cell sorting (FACS) plot of a representative sample, including CD3/CD56 and CD4/ CD8 subsets, expression of NKG2D, as well as inhibitory marker PD-1 and regulatory T-cell subsets, together with summary statistics for these subsets. No correlation could be found between the proportion of CD3
þ subset or size of regulatory T-cell subset with the observed cytotoxicity against the common AML blast target. Primary leukaemic cells were available for four patients for assay of their susceptibility to donor's CIK cell-killing. The cytotoxicities of the corresponding donor CIK cells for these four samples were lower than that against a common third- Of the 24 patients, 8 had CIK cells generated but did not receive CIK infusion for the following reasons: 2 patients (AML and CML in blast crisis) succumbed to treatment-related mortality, 3 (AML) had acute GVHD after chemotherapy or DLI, 2 (AML) had refractory disease deemed unsalvageable and 1 (AML) with very early relapse achieved a remission after withdrawal of immunosuppressants. We have previously demonstrated on pilot samples that freezing and thawing did not adversely affect the cytotoxicity of CIK cells (see Supplementary File 3). Post-thaw viability was a median 80.6%, which was 91.7% of prefreeze viability.
Response to CIK cell infusion Of the 24 patients, 8 had CIK cells generated but did not receive CIK infusion. Two patients (AML and CML in blast crisis) succumbed to treatment-related mortality, three (AML) had acute GVHD after chemotherapy or DLI, two (AML) had refractory disease deemed unsalvageable, and one (AML) with very early relapse achieved a remission after withdrawal of immunosuppressants. Table 2 shows the baseline characteristics, including initial treatment of relapse for the 16 patients who received allogeneic CIK infusion. Table 3 summarizes the details of clinical course after CIK cell infusion. Eight patients had at least one cycle of salvage chemotherapy before the first CIK cell infusion, whereas the other eight patients had only some mild oral palliative regimen, tyrosine kinase inhibitor or none at all. A total of 55 infusions, ranging between 1-12 infusions per patient, were given in an escalating dose from 10 to 200 million CD3 þ cells/kg, and a median dose of 30 million CD3 þ cells/kg. According to the definition for efficacy set above, no response was seen in six patients (AML no. 2, no. 3, no. 4, no. 5, no. 6, HD no. 1), including four (AML no. 3, no. 4, no. 5, HD no. 1) in whom only palliative oral chemotherapy at low doses was given. Three of these patients (AML no. 3, no. 5, no. 6) happened to also have leukaemic cells available for killing assay, which showed only modest cytotoxicity of donor CIK cells against these targets. Five patients (ALL no. 2, AML no. 1, AML no. 8, CML no. 1, NHL no. 1) fell into the 'unable to assess' group due to concomitant use of other agents that could produce the observed clinical result, such that any contribution by CIK cells could not be definitively concluded. We classified five patients as 'evidence suggestive of efficacy present' because the clinical course was suggestive of disease-controlling activity of CIK cells, the rationale of which is further elaborated as follows:
ALL no. 1. This patient had relapsed T-cell ALL that was refractory to four prior salvage regimens, including BerlinFrankfurt-Munich (BFM) R1 and R2, 21 fludarabine/ nelaralbine combination, 22 FLAG/idarubicin 23 with further allo-HSCT rescue, which contained a large number (162 million CD3
þ cells/kg) of T cells, followed by another DLI, but with persistence of 70% marrow blasts. The patient finally achieved a marrow remission after the fifth salvage regimen comprising of gemcitabine and mitoxantrone 24 followed by the first CIK cell infusion. After recovery from this cycle, a marrow remission was finally achieved and lasted for 10 months with repeated CIK infusions despite progressive extramedullary (EM) relapses involving shoulder joint, orbit, zygoma, pterygoid fossae and nasal sinuses. This illustrates an aggressive biology of the leukaemia manifesting as relentless progression at EM sites despite chemotherapy and CIK infusions. However, the fact that marrow could be maintained in remission despite EM progression is suggestive of the graft-vsleukemia (GVL) effect of CIK cells, as it is known that the immune-mediated GVL effect is only effective for marrow leukaemia, whereas ineffective for EM disease.
ALL no. 3. This patient who was induced into marrow remission by chemotherapy after relapsing from UCBT had further chemotherapy consolidation with the HyperCVAD regimen, 25 followed by CIK expanded from his own leukapheresed mononuclear cells after achieving marrow remission. The culture under CIK condition paradoxically yielded 98.3% CD3 À
CD56
þ NK cells from a starting subset of 10.3%. The marrow remained in remission for 5 months, while progressive leukaemia in the central nervous system developed within 1 month. Just like in the previous case, this could suggest an immune-mediated anti-leukaemic activity, maintaining disease control in the marrow, despite emergence of EM leukaemia reflecting an aggressive biology of the leukaemia.
HD no. 2. This patient had initial reduction of mediastinal and intra-abdominal lymph nodes with 3 cycles of oral VP-16 and pulse dexamethasone together with DLI, but this response was lost after the 4th DLI, manifesting as new lung nodules. She had two infusions of CIK cells at 3 and 6 months after the fourth DLI, which resulted in reduction in the size and number of lung nodules therefore suggesting an activity even after DLI failure. However, the response was not durable as the disease progressed 2 months after second CIK cell infusion, and was refractory to the third CIK cell infusion after which she finally succumbed. HD no. 3. This patient had three previous DLIs for mixed chimerism, which successfully converted him to full donor chimerism, but this did not prevent a relapse 3 months later in the abdominal nodes. The fourth DLI given after lowdose oral etoposide while awaiting preparation of CIK cells was therefore unlikely to contribute towards any meaningful response. The only CIK cell infusion given 1 month after DLI no. 4, also with oral etoposide and dexametha- sone, which were mild treatments unlikely to be of diseaseeradicative effect in the patient with multiple prior heavy treatment, resulted in shrinkage of the abdominal lymph nodes 1 month later and complete resolution 2 months later, which was again proven by positron-emission tomography (PET) scan done 6 months later. He continues to be in CR with no clinically evaluable disease now at 23 months from the CIK infusion. This is suggestive of efficacy of CIK cells in controlling disease after DLI failure.
AML no. 7. This is an unusual case where first relapse with the same chromosomal abnormalities as that at diagnosis occurred 10 years post transplant and was successfully treated with a standard AML induction protocol with idarubicin and cytarabin (3 þ 7). The second remission lasted for 2 years after which she relapsed a second time. This was salvaged with FLAG chemotherapy, followed by one dose of DLI 3 months later and subsequently 6 doses of monthly CIK infusion. She has since been in continuous CR3, now 31 months from the salvage chemotherapy, which is longer than the duration of CR2. By the natural history of acute leukaemia where disease-free interval is expected to be shorter with each relapse, the maintenance of remission may be attributable to the GVL effect of CIK infusions given to consolidate CR3.
Toxicity of CIK infusion
There was no adverse reaction associated with infusion of thawed CIK cells. The only side effect was a transient fever easily controlled with symptomatic measures not lasting beyond 24 h. Acute liver GVHD developed in two patients (HD no. 2 and HD no. 3) manifesting mainly elevated alkaline phosphatase and transaminases rather than jaundice, and one patient (AML no. 1) had a stage 3 GVHD of the skin and anorexia. GVHD occurred at D6 after the second CIK infusion at 50 million CD3 þ cells/kg for HD no. 2 and was controlled with a short course of prednisolone tapered over 1 month. For HD no. 3 it occurred at D67 from the CIK infusion at a dose of 30 million CD3/kg, and resolved spontaneously after confirmation by liver biopsy. AML no. 1 who did not respond to CIK infusion developed acute GVHD of skin at D6 after the 7th dose of CIK given at 100 million CD3 þ cells/kg, and responded promptly to a short course of prednisolone at 1 mg/kg. Two other patients (ALL no. 2 and AML no. 2) had pre-existing chronic GVHD before CIK infusion. Possible aggravation of the chronic GVHD by CIK infusion could not be ascertained, as ALL no. 2 succumbed to recurrent respiratory events contributed by infection, dasartinib toxicity or myopathy, and AML no. 2 succumbed soon to sepsis and respiratory failure.
Discussion
Our observations from this study provide evidence that in some instances, donor CIK is able to control disease more effectively than DLI. In real life practice due to advanced disease state and widely varied clinical condition of each patient, it is not feasible to dictate a fixed salvage protocol for all patients. Treatment modality and intensity have to be tailored according to the disease type, tempo of relapse, medical fitness and patient preference. CIK cells are often given following some form of salvage or palliative chemotherapy, in the former setting the resultant remission often could not be conclusively attributed to the activity of CIK cells. This was the case for the five patients in whom other concomitant effective treatments, including salvage chemotherapy (AML no. 1, AML no. 8 and NHL no. 1) and dasatinib (ALL no. 2 and CML no. 1) might alone result in the transient response observed. Notwithstanding, in five other patients we observed a clinical course suggestive of an anti-tumour activity, over and above what is normally expected from the concomitant conventional therapy as elaborated for each case above. Although the number was small and clinical scenario heterogeneous, the possible superiority over DLI in two of these patients (HD no. 2 and HD no. 3) support further studies along this line, where a larger number of convincing superior response may provide evidence for the upfront use of donor CIK cells.
One other noteworthy finding was the feasibility of generating allogeneic CIK cells from the leukapheresis product of patients who had no access to further donor cells. This therefore offers availability of donor cells in an activated form for patients who otherwise do not have the option of cellular therapy. Interestingly, we observed a higher proportion of CD3 þ CD56 þ subset in allogeneic CIK cells derived from patients. T cells from AML patients undergoing chemotherapy express higher percentage of activation markers such as CD25 and CD69 and have increased proliferative capacity to CD3 and CD28 costimulation as compared with the healthy donors, 26 which may explain the better expansion.
It was obvious that CIK cells, just like DLI, were ineffective against rapidly relapsing acute leukaemia without any salvage chemotherapy, and therefore should not be used alone for relapsed acute leukaemia. More indolent disease like lymphoma may still be amenable to the slow action of cellular immunotherapy, such as that observed for the two patients with relapsed HD described here. It was also observed that, just like the Graft vs tumour effect of DLI, 27 CIK cells seemed to be ineffective in controlling EM diseases despite its activity in controlling marrow leukaemia, as demonstrated in ALL no. 1 and ALL no. 3.
One reassuring observation was that CIK cells were welltolerated in terms of infusional side effect and did not cause more acute GVHD than DLI. The lower incidence of GHVD of allogeneic CIK cells have been convincingly shown in mouse models, 28 and was postulated to be due to less trafficking of CIK cells to GVHD sites. 29 This was also consistent with an earlier report on activated donor lymphocytes expanded with CD3/CD28 coated beads, where GVHD was observed in 7 out of 18 patients. 17 In two Phase I studies using allogeneic CIK for relapsed patients, acute GVHD occurred in 4 out of 11 patients 30 and 1 out of 10 patients, 16 respectively. Although our small series has provided some evidence suggestive of activity of donor CIK cells, the efficacy is only modest and far from satisfactory. Three of the five patients who responded experienced eventual progression of dis-ease. The abundant pre-clinical work on CIK cells may provide strategies for improving the efficacy and specificity of the treatment. This includes co-culture of CIK cells with tumour-Ag pulsed DCs, 31, 32 bispecific antibodies to redirect CIK cells to tumour target, 33, 34 or engineering CIK cells to express anti-CD19 receptor. 35 Exploiting the heterogeneous subsets within the bulk CIK cell culture is another avenue for enhancing its potency. The small NK subset within the bulk CIK culture complements T cells in the killing of targets that may escape T-cell surveillance by downregulation of Class I Ag. 36 By complement-and Ab-dependent cytotoxicity mediated by NK subset within CIK culture, it was recently shown that combination with anti-CD20 Ab further enhanced their anti-lymphoma activity. 37 Other strategies include timing of infusion to coincide with nadir of lymphopenia for maximal homoeostatic expansion of adoptively transferred T cells. 38, 39 With close collaboration between research scientists and transplant haematologists, the research findings on CIK cells can be translated into clinical protocols for maximal benefit in the prevention and treatment of relapse postallo-HSCT.
